Conclusion Probiotic/synbiotic use  improves aminotransaminase levels and reduces proinflammatory marker high-sensitivity C-reactive protein and liver fibrosis in NAFLD patients
Background Nonalcoholic fatty liver disease ( NAFLD ) is the most prevalent chronic liver disease worldwide .
The pathogenesis of NAFLD is complex and multifactorial .
There is growing evidence that altered gut microbiota plays a key role in NAFLD progression .
Probiotics/synbiotics , by modifying gut microbiota , may be a promising treatment choice for NAFLD management .
Aim The aim of this study was to study the effect of probiotics/synbiotics on various laboratory and radiographic parameters in NAFLD management .
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Flaws in the design , conduct , analysis , and reporting of r and omised trials can cause the effect of an intervention to be underestimated or overestimated . The Cochrane Collaboration ’s tool for assessing risk of bias aims to make the process clearer and more
Conclusion Probiotic/synbiotic use  improves aminotransaminase levels and reduces proinflammatory marker high-sensitivity C-reactive protein and liver fibrosis in NAFLD patients
Background Nonalcoholic fatty liver disease ( NAFLD ) is the most prevalent chronic liver disease worldwide .
The pathogenesis of NAFLD is complex and multifactorial .
There is growing evidence that altered gut microbiota plays a key role in NAFLD progression .
Probiotics/synbiotics , by modifying gut microbiota , may be a promising treatment choice for NAFLD management .
Aim The aim of this study was to study the effect of probiotics/synbiotics on various laboratory and radiographic parameters in NAFLD management .